The present invention relates to a method for producing a molecule of interest in bacteria which is based on reversible growth arrest of the bacteria at cellular growth global control system level, thus allowing an improved yield of production of said molecule of interest.

Provided are a beta prime subunit mutant of RNA polymerase, a microorganism of the Corynebacterium genus including a polynucleotide coding the same, and a method for producing L-lysine by culturing the same.

The present application relates to an L-threonine-producing microorganism and a production method for L-threonine using the same, and more specifically, to a microorganism having enhanced L-threonine productivity and a method for producing L-threonine in high yield using the same.

The present disclosure relates to polynucleotides comprising a nucleic acid sequence encoding a replication competent viral genome, wherein the polynucleotide is capable of producing a replication competent virus when introduced into a cell by a non-viral delivery vehicle. The present disclosure further relates to the encapsulation of the polynucleotides and the use of the polynucleotides and/or particles for the treatment and prevention of cancer.

Compositions comprising modified recombinant polymerizing enzymes are provided, along with nucleic acid molecules encoding the modified polymerizing enzymes. In some aspects, methods of using such polymerizing enzymes to synthesize a nucleic acid molecule or to sequence a nucleic acid template are provided.

The present invention provides, among other things, improved methods and pharmaceutical compositions for treating cystic fibrosis based on codon optimized mRNA encoding a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein.

The disclosure provides methods, compositions, systems, and kits for the concurrent detection and analysis of different structural and chemical forms of nucleic acids in a sample.

The present invention provides engineered RNA polymerase variants and compositions comprising these variants. The present invention further provides engineered T7 RNA polymerase variants and compositions comprising these variants. These variants have been evolved for selective incorporation of the m7G(5′)ppp(5′)m7G cap analog over GTP at the initiation of in vitro transcription. The present invention also provides methods for selective capping of RNA transcripts.

A bacteriophage RNA polymerase variant is provided. In some embodiments, the variant may have increased thermostability relative to the corresponding wild type bacteriophage RNA polymerase and/or wild type T7 RNA polymerase. Compositions, kits and methods that employ the variant are also provided.

The present disclosure provides compositions and methods for performance of targeted mutagenesis in higher eukaryotic cells, e.g., mammalian cells, across large stretches of targeted sequence. Compositions and methods that rely upon combination of a bacteriophage polymerase with a nucleic acid-editing deaminase to achieve robust mutagenesis of targeted regions of nucleic acid sequence under control of a phage promoter are specifically provided.